文献速递免疫规划传染病防控与疫情报告

一种基于单嵌合病毒样颗粒共同展示多种保守表位的新型联合疫苗用于预防肠道病毒71型和水痘-带状疱疹病毒感染

A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
PubMed 文献 · Vaccine · 2017-04-10

研究构建了三种基于乙型肝炎核心抗原(HBc)载体的嵌合病毒样颗粒(VLP),分别以不同串联方式展示水痘-带状疱疹病毒(VZV)gE、肠道病毒71型(EV71)VP1和VP2的表位。其中HBc-V/1/2能诱导针对三种表位的平衡抗体反应且无免疫干扰,其抗血清可同时中和VZV和EV71并交叉中和柯萨奇病毒A16(CVA16),并保护新生小鼠免受EV71和CVA16致死性攻击。研究表明HBc-V/1/2是手足口病和水痘的候选联合疫苗。

要点

  • HBc-V/1/2嵌合VLP可自组装并表面展示VZV-gE、EV71-VP1和EV71-VP2表位。
  • HBc-V/1/2诱导针对三种表位的平衡抗体反应,未观察到表位间免疫干扰。
  • 抗HBc-V/1/2血清同时中和VZV和EV71,交叉中和CVA16,并保护新生小鼠。

核心结论

  • HBc-V/1/2是有望用于手足口病和水痘的候选联合疫苗,并提供联合疫苗设计新策略。

研究设计与样本

  • 基于乙型肝炎核心抗原(HBc)载体构建三种嵌合VLP:HBc-V/1/2、HBc-2/V/1和HBc-1/2/V,以不同串联方式展示VZV-gE、EV71-VP1和EV71-VP2表位。

主要发现

  • 表位特异性抗体表征显示HBc-V/1/2诱导针对三种表位的平衡抗体反应,未观察到三种表位间免疫干扰。
  • 抗HBc-V/1/2血清可同时中和VZV和EV71,并交叉中和CVA16。
  • 抗HBc-V/1/2血清保护新生小鼠免受EV71和CVA16致死性攻击。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chicken pox and hand, foot and mouth disease (HFMD) are two major infectious diseases that mainly affect infants and children, causing significant morbidity annually. Varicella-zoster virus (VZV) and enterovirus 71 (EV71), respectively, are the principal epidemic pathogens causing these two diseases. To investigate the possibility of developing a novel combined vaccine to prevent chicken pox and HFMD, we constructed three chimeric virus-like particles (VLPs) (termed HBc-V/1/2, HBc-2/V/1 and HBc-1/2/V) based on the hepatitis B core antigen (HBc) carrier that display epitopes derived from VZV-gE, EV71-VP1, and EV71-VP2 in a varied tandem manner. The chimeric HBc can self-assemble into VLPs with these three epitopes displayed on the surface of particles. Epitope-specific antibody characterization suggested that HBc-V/1/2 elicits a balanced antibody response toward these three epitopes, and no immune interference was observed between the three epitopes. Importantly, the anti-HBc-V/1/2 sera could simultaneously neutralize VZV and EV71 and cross-neutralize coxsackievirus A16 (CVA16), another major pathogen causing HFMD. Moreover, the anti-HBc-V/1/2 sera protected neonatal mice from lethal challenge of EV71 and CVA16. Collectively, our study not only demonstrated that HBc-V/1/2 is a promising candidate combined vaccine for HFMD and Chicken pox but also provides a novel strategy for the design of combined vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wu Y, Zhu R, Xu L, et al. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine. 2017. PMID: 28408118. doi:10.1016/j.vaccine.2017.03.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。